Pharmafile Logo

Webcast: Biosimilars: Friend or Foe to Healthcare?

March 31, 2015 | Biologics 

Understanding the opportunities for biosimilars and the threats to innovator biologics

Referencing recent findings from our Therapy Watch syndicated study in RA, this webcast investigates physicians’ perceptions of the biosimilars market. Therapy Watch Director Allison Fleetwood and Access Partnership Director Shrinivas Rao Mukku interview a major US payer, who offers expert opinion on the opportunities for biosimilars in the US market, the possible threats to originator brands, and consider what companies entering the market need to do to effectively launch their follow-on biologic.

Furthermore, this webcast looks into how the launch of mAb biosimilars in Europe may impact on healthcare strategies in the US, and how to overcome the challenges biosimilars face if they are to achieve sufficient uptake.

What you will learn:

  • Better understand physician awareness and familiarity with biosimilars and the potential barriers to uptake 
  • Learn about the strengths and weaknesses of biosimilars and the impact they may have on the treatment landscape from the payer perspective 
  • Gain greater insight into what companies entering the market need to do to effectively launch their follow-on biologic

To view this webinar please visit http://bit.ly/WBnezg 

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

The Next Billion Patients

Marc Yates, Director of Emerging Markets at pharma market research specialist Research Partnership, shares insights from his experience of working in BRIC and beyond.

Huge Untapped Growth Potential of ASEAN

Marc Yates, Director of Emerging Markets at pharma market research specialist Research Partnership, shares insights from his experience of working in BRIC and beyond.

The power of observation in gathering patient insights

Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding.

Market Insights Can Deliver a Better Patient Experience

Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding

Excellence in oncology: Developing an effective biomarker strategy

Oncology is arguably the most exciting area of medicine in which to be working today. Biomarkers and companion diagnostics offer incredibly valuable predictive power, which is of benefit to payers,...

Warehousing of HCV patients reaches new high

A new study conducted by Research Partnership reveals that 90% of physicians treating HCV patients in the US have reported they are now “warehousing” patients (holding off treatment) in expectation...

Brand leaders in RA will lose market share, predict rheumatologists

Rheumatologists believe that the current market for biologic treatments in Rheumatoid Arthritis (RA) will see key changes in the next three years.

Removing the Roadblocks to Effective Patient Treatment

How can pharma benefit from improved patient understanding? Welcome to a new column in which Mary Assimakopoulos, Founding Director of pharma market research specialist the Research Partnership reveals findings from...

Driving Earlier Diagnosis: A Case Study in Psoriatic Arthritis

Following a survey of 1000 Psoriatic Arthritis patients, Mary Assimakopoulos shares some of the root causes behind a late diagnosis of this debilitating illness, and the patients’ own feelings towards...

The Difficulties of Living with Depression Don’t End with the Illness Itself

This month Mary Assimakopoulos examines some of the insights gathered while surveying 2,000 patients suffering with this often misunderstood mental illness.